EMA Authorised: Integrilin (eptifibatide) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

Authorised by EMA: Integrilin (eptifibatide) approved for unstable angina and myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Unstable Angina

Drugs mentioned

• Integrilin (Eptifibatide)

Snippet

Status: Authorised. Therapeutic area: Angina, Unstable;Myocardial Infarction. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 24/09/2021